Alpha Tau Medical (NASDAQ:DRTSW – Get Free Report) and STAAR Surgical (NASDAQ:STAA – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.
Analyst Recommendations
This is a summary of current recommendations for Alpha Tau Medical and STAAR Surgical, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alpha Tau Medical | 0 | 0 | 0 | 0 | 0.00 |
| STAAR Surgical | 3 | 7 | 2 | 1 | 2.08 |
STAAR Surgical has a consensus price target of $28.40, indicating a potential upside of 22.73%. Given STAAR Surgical’s stronger consensus rating and higher possible upside, analysts plainly believe STAAR Surgical is more favorable than Alpha Tau Medical.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alpha Tau Medical | N/A | N/A | N/A | N/A | N/A |
| STAAR Surgical | $239.44 million | 4.85 | -$80.45 million | $0.07 | 330.57 |
Alpha Tau Medical has higher earnings, but lower revenue than STAAR Surgical.
Profitability
This table compares Alpha Tau Medical and STAAR Surgical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alpha Tau Medical | N/A | N/A | N/A |
| STAAR Surgical | 1.13% | 9.05% | 6.99% |
Insider and Institutional Ownership
96.7% of STAAR Surgical shares are held by institutional investors. 39.9% of STAAR Surgical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
STAAR Surgical beats Alpha Tau Medical on 10 of the 10 factors compared between the two stocks.
About Alpha Tau Medical
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.
About STAAR Surgical
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
